| |
|
|
|
|
|
|
|||
|
Blood, 15 February 2006, Vol. 107, No. 4, pp. 1434-1444. Prepublished online as a Blood First Edition Paper on October 27, 2005; DOI 10.1182/blood-2004-09-3445.
Submitted September 7, 2004
Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany; Cellular Immunology, Institute for Genetics, University of Cologne, Cologne, Germany * Corresponding author; email: Irmgard.Foerster{at}uni-duesseldorf.de.
MHC class II (MHCII) deficiency or Bare Lymphocyte Syndrome (BLS) is a severe immunodeficiency characterized by deficient T helper (Th) cell dependent immunity. The disease is caused by defects of the MHCII promoter complex resulting in low or absent MHCII expression. We demonstrate in a murine model of MHCII deficiency (RFX5- or CIITA-deficient mice) that residual MHCII expression by professional APC is sufficient to support activation of adoptively transferred Th cells. Furthermore, upon transplantation of WT thymic epithelium we observed development of endogenous Th cells with restoration of Th cell dependent antibody responses and immunity to cytomegalovirus infection, thus opening the possibility of an alternative treatment regimen for MHCII deficiency. Residual MHCII expression was further induced by the presence of Th cells and also other stimuli. Analysis of CIITA/RFX5 double deficient animals revealed that this inducible MHCII expression is genetically independent of the known promoter complex and thus constitutes an alternative MHCII expression pathway. In these experiments, we also detected a novel repressive function of the RFX complex in the absence of CIITA.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||